Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2965 - Accuracy of plasma RAS mutation testing for therapy selection and monitoring of colorectal cancer patients


08 Oct 2016


Poster Display


JOANA Vidal Barrull


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


J. Vidal Barrull1, L. Muinelo Romay2, A. Dalmases3, A. Abalo2, M.C. Vela3, M. Abreu Rodríguez2, M. Muset3, J. Ruiz2, M. Iglesias3, C. Blanco2, E. López1, C. Rodríguez2, F.S. Jones4, D. Edelstein4, A. Lukas5, J. Albanell1, B. Bellosillo3, S. Candamio2, C. Montagut1, R. López2

Author affiliations

  • 1 Medical Oncology, University Hospital del Mar, 08003 - Barcelona/ES
  • 2 Translational Medical Oncology Group, Health Research Institute Of Santiago (idis), Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, 15706 - Santiago de Compostela/ES
  • 3 Pathology Department, University Hospital del Mar, 08003 - Barcelona/ES
  • 4 Clinical Scientific Affairs, Sysmex Inostics, 21205 - Baltimore/US
  • 5 Research & Development, Sysmex Inostics, Sysmex Inostics GmbH, 20251 - Hamburg/DE


Abstract 2965


Tumor tissue is currently used for RAS testing in metastatic colorectal cancer (mCRC) patients, but detection of circulating tumor DNA in plasma is being actively investigated as an alternative for detection and monitoring of RAS mutations during therapy.


Concordance of plasma and tissue RAS mutation was evaluated in 102 mCRC patients. RAS mutation status was also monitored in serial plasma samples from 18 patients. The OncoBEAM™ RAS CRC assay was used to detect RAS mutations in plasma and results were compared to those obtained by standard-of-care RAS testing of tissue. For discordant cases, tissue samples were re-examined with BEAMing.


The overall percent agreement of the two methods was 93.1% (95/102 patients), with positive agreement of 95.6% (43/45) and negative agreement of 91.2% (52/57). Of the 5 plasma+/tissue cases, 3 patients were treated with anti-EGFR therapy; 2 showed responses with loss of RAS mutations in plasma and 1 patient did not respond to therapy. In another plasma+/tissue case, tissue BEAMing revealed a RAS mutation. This patient was treated with anti-VEGF therapy with a partial response. Longitudinal monitoring of plasma RAS status showed that of 13 patients initially treated with cetuximab, 4 showed emergence of RAS mutations at progression. In 4 other patients with basal RAS mutations treated with QT + anti-VEGF, 3 showed a significant decrease in the fraction of RAS mutant alleles. This decline mirrored responses to treatment. Interestingly, all 4 of these patients were determined to have stable disease by RECIST criteria upon CT scan.

Positive Negative total
PLASMA RAS Positive 43 5 48
Negative 2 52 54
Total 45 57 102


The high overall agreement between plasma and tissue RAS mutation status indicates that blood-based testing with OncoBEAM™ RAS CRC is a viable alternative to tissue testing for mCRC patients. Moreover, this study shows that BEAMing will be useful to monitor RAS mutation status in patients undergoing systemic therapy to monitor resistance and evaluate the efficacy of particular treatments.

Clinical trial identification

Legal entity responsible for the study

Cancer Program, IMIM-Hospital del Mar, Barcelona, Spain


Cancer Program, IMIM-Hospital del Mar, Barcelona, Spain Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS). Complexo Hospitalario Universitario de Santiago de Compostela, Spain


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings